Form 4: Syra Health Corp Director Acquires Stock Options

A Syra Health Corp director, Sherron Rogers, acquired 9,102 stock options at an exercise price of $0.7386 on January 7, 2025.

Summary

• Sherron Rogers, a director at Syra Health Corp, acquired 9,102 stock options on January 7, 2025.
• The exercise price for these options is $0.7386 per share.
• The options were granted under the company's 2022 Omnibus Equity Incentive Plan.
• 25% of the options vested immediately, and the remaining options will vest in 12 equal monthly installments.
• Following this transaction, Rogers directly owns 20,683 shares of Syra Health Corp.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of a stock option grant to a director. It is neither particularly positive nor negative, but indicates a standard practice of incentivizing management.

Positives

• The acquisition of stock options by a director can be seen as a positive sign of confidence in the company's future performance.
• The vesting schedule of the options may incentivize the director to remain engaged with the company.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in publicly traded companies as part of their compensation and incentive programs.
• The vesting schedule of 25% immediately and the remainder over 12 months is a fairly standard vesting schedule.
• The exercise price of $0.7386 is specific to Syra Health Corp and would need to be compared to the current market price of the stock to assess its value.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, insider trading, equity incentive plan, director, Syra Health Corp, beneficial ownership